LARGO, Fla. - CONMED Corporation (NYSE:CNMD) announced today the appointment of John E. Gallagher as Chief Financial Officer, effective July 15, 2026, according to a press release statement. Gallagher will succeed Todd Garner, who will remain with the medical technology company in an advisory capacity through November 2, 2026.
Gallagher brings nearly 30 years of financial experience across healthcare and industrial companies. He most recently served as CFO of Certara, Inc., a pharmaceutical technology and services company, beginning in 2023. Prior to that role, he was CFO of Cue Health Inc., a healthcare technology company, from 2021 to 2023.
Before his CFO positions, Gallagher spent nine years at Becton, Dickinson & Co., where he held multiple roles. He joined BD in 2012 as Corporate Treasurer and later served as Controller and Chief Accounting Officer. In 2018, he was promoted to Senior Vice President and CFO of BD’s Medical Segment. Earlier in his career, Gallagher held finance leadership positions at General Electric Company and Ford Motor Company.
Gallagher holds an MBA from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh and a Bachelor of Science in Finance from Clemson University.
"We are pleased to welcome a talented and experienced financial executive of John’s caliber to CONMED," said Patrick J. Beyer, CONMED’s President and Chief Executive Officer.
CONMED is a medical technology company that provides devices and equipment for surgical procedures used in specialties including orthopedics, general surgery, gynecology, and thoracic surgery. The company, with a market capitalization of $959 million, has seen its stock decline 33.6% over the past year to $32.11, trading near its 52-week low of $32.13. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment, placing it among opportunities on the Most Undervalued stocks list. InvestingPro subscribers have access to over 8 additional exclusive tips for CNMD, plus comprehensive Pro Research Reports covering 1,400+ top US stocks with actionable intelligence for smarter investing decisions.
In other recent news, Conmed Corporation reported first-quarter 2026 earnings that exceeded analysts’ expectations, with adjusted earnings per share at $0.89, surpassing the forecasted $0.82. The company also achieved a revenue of $317 million, slightly above the anticipated $310.59 million. Additionally, Conmed has secured a $450 million term loan facility to repurchase convertible notes, as part of an amendment to its existing credit agreement. This loan facility, administered by JPMorgan Chase Bank, N.A., is available for a single transaction until June 14, 2026, and matures on June 10, 2030.
In corporate governance developments, Conmed announced the appointment of Celine Martin and Jeff Mirviss to its board of directors, effective July 1, 2026. Martin will join the audit and strategy committees, while Mirviss will serve on the compensation and corporate governance and nominating committees. These appointments will expand the board from seven to nine directors. These developments reflect ongoing strategic and financial maneuvers by Conmed in the current business environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates CNMD alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if CNMD is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?